相关实验视频

Updated: Jul 9, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

利用全抑制:通过基于药的虚拟查和基本分子动态来优先考虑针对癌症治疗的LIMK2抑制剂

Raghu Rangaswamy¹, Nagarajan Hemavathy¹, Sneha Subramaniyan¹

¹Structural Biology and Bio-Computing Lab, Department of Bioinformatics, Alagappa University, Karaikudi, Tamil Nadu, India.

Journal of biomolecular structure & dynamics

|December 8, 2023

概括

这项研究确定了两种新型全抑制剂,ZINC1433610862和ZINC1044382792,用于LIMK2,这是癌症治疗的关键标. 这些化合物具有很高的结合亲和力和有利的特性,为新的癌症治疗提供了有希望的线索.

科学领域:

药用化学医学化学
计算机化药物发现技术
分子生物学分子生物学

背景情况:

激酶抑制剂在癌症治疗中至关重要,但由于类似的ATP结合部位,选择性是一个主要障碍.
阿洛斯特抑制提供了一个有希望的策略,通过准替代的绑定口袋来克服选择性挑战.

研究的目的:

确定和优先考虑LIMK2 (LIM域含蛋白2) 的3型全抑制剂.
利用计算方法来有效地发现药物,目标是LIMK2.

主要方法:

利用了电子药模拟,高通量虚拟选 (HTVS) 与ZINC数据库对比,以及ADMETox分析.
采用分子动力学 (MD) 模拟,密度函数理论 (DFT) 和MM/PBSA来进行具有约束力的自由能量计算.
专注于识别与神秘的LIMK2口袋残留物Asp469和Arg474.4相互作用的抑制剂.

主要成果:

建立了一个具有五个关键特征 (RRRAH) 的电子药理模型.
最初确定了五种化合物,其中ZINC1433610862和ZINC1044382792显示出优越的结合亲和力和稳定性.
MD模拟证实了ZINC1433610862和ZINC1044382792与关键LIMK2残留物的稳定键相互作用.
计算的结合自由能量为ZINC1433610862的 -90.122 ± 1.248 kJ/mol,而ZINC1044382792的 -83.491 ± 1.230 kJ/mol.

结论:

ZINC1433610862和ZINC1044382792被确定为针对LIMK2.2的有希望的化合物.
这些全抑制剂显示出开发具有提高选择性的新型癌症治疗药物的潜力.

关键词:

在LIMK2中,LIMK2是指LIMK2.这是一种3型抑制剂.分子动力学模拟模拟药物学家查药物学家查

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...